Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use
Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma
In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life
Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity
Diverse approaches are investigated in oncology that also include the use of artificial intelligence
Epigenetic information could harbour biomarkers of diagnosis and prognosis
Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment
A toolkit to address disparities in digitally enabled oncology trials
An initiative fosters inclusive research by improving patient access and participation in cancer research
AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Lamarca: “Understanding the problem is the first step to solving it”
Career growth is a step-by-step journey, built on resilience, clarity, and the ability to face challenges head-on - because success never happens overnight
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process
The updated ESMO-MCBS captures the evolving treatment landscape and patient priorities
The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits